TWI829677B - 新型抗pd-1抗體 - Google Patents

新型抗pd-1抗體 Download PDF

Info

Publication number
TWI829677B
TWI829677B TW108109186A TW108109186A TWI829677B TW I829677 B TWI829677 B TW I829677B TW 108109186 A TW108109186 A TW 108109186A TW 108109186 A TW108109186 A TW 108109186A TW I829677 B TWI829677 B TW I829677B
Authority
TW
Taiwan
Prior art keywords
amino acid
acid sequence
seq
sequence shown
binding molecule
Prior art date
Application number
TW108109186A
Other languages
English (en)
Chinese (zh)
Other versions
TW202003563A (zh
Inventor
蘊穎 陳
競 李
Original Assignee
大陸商上海藥明生物技術有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 大陸商上海藥明生物技術有限公司 filed Critical 大陸商上海藥明生物技術有限公司
Publication of TW202003563A publication Critical patent/TW202003563A/zh
Application granted granted Critical
Publication of TWI829677B publication Critical patent/TWI829677B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW108109186A 2018-03-20 2019-03-18 新型抗pd-1抗體 TWI829677B (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN201810255570.3 2018-03-20
CN201810255570 2018-03-20
CN2018079631 2018-03-20
WOPCT/CN2018/079631 2018-03-20

Publications (2)

Publication Number Publication Date
TW202003563A TW202003563A (zh) 2020-01-16
TWI829677B true TWI829677B (zh) 2024-01-21

Family

ID=67986701

Family Applications (1)

Application Number Title Priority Date Filing Date
TW108109186A TWI829677B (zh) 2018-03-20 2019-03-18 新型抗pd-1抗體

Country Status (7)

Country Link
US (2) US12030941B2 (https=)
EP (1) EP3768724A4 (https=)
JP (2) JP7482031B2 (https=)
CN (2) CN116333126A (https=)
CA (1) CA3093992A1 (https=)
TW (1) TWI829677B (https=)
WO (1) WO2019179396A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116333126A (zh) * 2018-03-20 2023-06-27 上海药明生物技术有限公司 新型抗pd-1抗体
CN112442122B (zh) * 2019-09-04 2021-09-21 上海洛启生物医药技术有限公司 阻断型pd-1纳米抗体及其编码序列和用途
CN114430746B (zh) * 2019-09-25 2023-09-01 上海药明生物技术有限公司 新型抗pd-l1抗体
WO2021063201A1 (zh) * 2019-09-30 2021-04-08 四川科伦博泰生物医药股份有限公司 抗pd-1抗体及其用途
BR112022023989A2 (pt) 2020-05-26 2023-02-07 Boehringer Ingelheim Int Anticorpos anti-pd-1
CN118240082A (zh) * 2020-12-28 2024-06-25 浙江纳米抗体技术中心有限公司 Pd-1结合分子及其应用
US20240092908A1 (en) * 2020-12-31 2024-03-21 Zhejiang Doer Biologics Co., Ltd. Anti-pd-1 single-domain antibody
WO2022161454A1 (zh) * 2021-01-29 2022-08-04 明慧医药（杭州）有限公司 抗原结合蛋白及其用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106046162A (zh) * 2016-06-21 2016-10-26 大庆东竺明生物技术有限公司 抗人程序性死亡因子1（pd‑1）单克隆抗体的制备及应用
CN107474135A (zh) * 2017-02-17 2017-12-15 广西医科大学 抗PD‑1的纳米抗体PD‑1/Nb20及其制备方法与应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2494107C2 (ru) * 2005-05-09 2013-09-27 Оно Фармасьютикал Ко., Лтд. Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами
WO2009114335A2 (en) * 2008-03-12 2009-09-17 Merck & Co., Inc. Pd-1 binding proteins
CN105061597B (zh) * 2015-06-09 2016-04-27 北京东方百泰生物科技有限公司 一种抗pd-1的单克隆抗体及其获得方法
CN106432494B9 (zh) 2015-08-11 2022-02-15 广州誉衡生物科技有限公司 新型抗-pd-1抗体
MA43260A (fr) * 2015-11-18 2018-09-26 Merck Sharp & Dohme Liants pd1 et/ou lag3
AR114127A1 (es) * 2018-03-02 2020-07-22 Lilly Co Eli Anticuerpos agonistas contra pd-1 y usos de estos
CN116333126A (zh) * 2018-03-20 2023-06-27 上海药明生物技术有限公司 新型抗pd-1抗体

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106046162A (zh) * 2016-06-21 2016-10-26 大庆东竺明生物技术有限公司 抗人程序性死亡因子1（pd‑1）单克隆抗体的制备及应用
CN107474135A (zh) * 2017-02-17 2017-12-15 广西医科大学 抗PD‑1的纳米抗体PD‑1/Nb20及其制备方法与应用

Also Published As

Publication number Publication date
EP3768724A4 (en) 2022-04-13
CN112236454B (zh) 2022-09-13
JP2021518137A (ja) 2021-08-02
TW202003563A (zh) 2020-01-16
CA3093992A1 (en) 2019-09-26
CN112236454A (zh) 2021-01-15
US12030941B2 (en) 2024-07-09
EP3768724A1 (en) 2021-01-27
WO2019179396A1 (en) 2019-09-26
US20210061912A1 (en) 2021-03-04
CN116333126A (zh) 2023-06-27
US20240301067A1 (en) 2024-09-12
JP7482031B2 (ja) 2024-05-13
JP2024029261A (ja) 2024-03-05

Similar Documents

Publication Publication Date Title
TWI829677B (zh) 新型抗pd-1抗體
CN112480248B (zh) 与cld18a2特异性结合的分子
CN110204614B (zh) 抗人lag-3单克隆抗体及其制备方法和用途
TWI831778B (zh) 抗ox40的全人抗體及其製備方法和用途
WO2020238730A1 (zh) 新型cldn18.2结合分子
CN111978402B (zh) 新型cldn18.2结合分子
US20240067725A1 (en) Monoclonal antibody against human lag-3, method for preparing same, and use thereof
US12570746B2 (en) Anti-PD-L1 antibodies
CN111978403B (zh) 新型cldn18.2结合分子
CN113214400A (zh) 一种双特异性抗pd-l1/vegf抗体及其用途
CN112552411B (zh) 新型抗pd-l1/抗lag-3双特异性抗体及其用途
TW202144397A (zh) 一種雙功能融合蛋白及其用途
HK40044140B (en) Novel anti-pd-1 antibodies
WO2024146553A1 (en) Antibodies against cd47, method for preparing the same, and use thereof
HK40044140A (en) Novel anti-pd-1 antibodies
AU2024286100A1 (en) Anti-tigit antibodies and uses thereof
HK40033235A (en) Novel cldn18.2 binding molecule
HK40032484A (en) Novel cldn18.2 binding molecule
CN118047869A (zh) 抗pd-l1抗体及其用途
HK40032484B (en) Novel cldn18.2 binding molecule